Nuvectis Pharma Financials - Benzinga

Nuvectis Pharma Inc

NVCTNASDAQ

Trade with Public

Trade with Public

$23.33

2.4211.57%

At close: Aug 18, 5:00 PM EST

$21.45

0.542.58%

Pre-Market: 7:56 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Nuvectis Pharma Financials

Nuvectis Pharma (NVCT) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Nuvectis Pharma Q2 EPS $(0.30) Misses $(0.26) Estimate

Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.26) by 15.38 percent. This is unchanged from the same period last year.

Benzinga Newsdesk

PRO
Nuvectis Pharma Q1 EPS $(0.26) Beats $(0.32) Estimate

Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.32) by 18.75 percent. This is a 3.7 percent increase over losses of $(0.27) per share from the

Benzinga Newsdesk

PRO
Nuvectis Pharma Q4 EPS $(0.31), Inline

Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.31) per share which met the analyst consensus estimate. This is a 13.89 percent increase over losses of $(0.36) per share from the same period last year.

Benzinga Newsdesk

PRO
Nuvectis Pharma Q3 EPS $(0.44) Misses $(0.25) Estimate

Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.25) by 73.91 percent. This is a 83.33 percent decrease over losses of $(0.24) per share from

Benzinga Newsdesk

PRO
Nuvectis Pharma Q2 EPS $(0.30) Misses $(0.26) Estimate

Benzinga Newsdesk

PRO
Nuvectis Pharma Q1 EPS $(0.27) Misses $(0.25) Estimate

Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.25) by 8 percent. This is a 8 percent decrease over losses of $(0.25) per share from the

Benzinga Newsdesk